NARI

Inari Medical, Inc. (NARI) | Rumor.io

Inari Medical

NARI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NARI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 17

The author believes $NARI has the potential to reach 137x+ and has been hitting new highs, with a recent 8K filing and significant increase in market capitalization.
The author has analyzed the top holders and team behind Inari Medical, Inc. and is confident in their price prediction, although a recent report suggests a high risk of rug pulls.
The author is optimistic about the future of $NARI, citing Elon Musk's involvement and the token's potential to become the next Grok Companion, with some analysts predicting a significant price increase.

Generated by AI

Sentiment

Of the messages about NARI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.17% +9.77
Bearish	—	—	—	1.83% -9.77

Bullish· Jan 8

The company's technology is considered good and has the backing of a respected top doctor in NYC.
The asset is undervalued and could be worth more than a billion dollars.
The stock could be an acquisition candidate for a larger company, similar to other medical tech companies that were previously out of favor.

Bearish· Nov 2

$NARI's price action is seen as irrational after upbeat guidance, with some investors adding positions around the 50 area.
The market is concerned about the company's acquisition, with some investors feeling that it will divert focus from the core business.
The stock's technical chart shows vulnerability, with a sell-off and significant volume, potentially indicating that a whale is betting against the stock.

Generated by AI

Topics

Of the messages about NARI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	43.57%
Announcements	—	—	—	12.35%
Controversies	—	—	—	0.23%
Earnings	—	—	—	0%
Macro	—	—	—	43.8%
Technical Analysis	—	—	—	0.06%

Earnings· Jan 9

NARI's preliminary Q4 revenue of $132.0M is up approximately 22% YoY, beating expectations.
Full-year 2023 revenue of $493.5M represents a 29% increase over 2022.
Inari Medical expects full-year 2024 revenue of $580M-$595M, reflecting continued growth.

Analysts· Mar 10

Morgan Stanley raised its price target for NARI to $126, maintaining an overweight rating.
BTIG Research raised its price target for NARI to $135, citing 65% year-over-year sales growth, and maintains a buy rating.
Canaccord Genuity raised its price target for NARI to $129, reiterating a buy rating.

Announcements· Jan 8

Stryker has agreed to acquire Inari Medical, Inc. (NARI) for $4.9 billion.
The deal involves Stryker purchasing Inari Medical, a medical device innovator, to expand its offerings in the field.
The acquisition is expected to enhance Stryker's capabilities in treating blood clots.

Generated by AI

Community

Of the messages about NARI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	83.33%	37.76%
Newcomers	100%	100%	16.67%	62.24%

Regulars· Jan 7

NARI was acquired by Stryker in an all-cash deal worth $4.9 billion, with a tender offer for $80 per share, a 60.74% premium.
Long-term investors are advised to "Buy low and Sell high" as NARI's stock has experienced dips below $40 in the past 12 months, and the buyout may be a good omen for the overall Biotech market.
NARI's acquisition by Stryker is reminiscent of the disappointing medtech acquisition of Volcano, with both experiencing multi-year drawdowns and disappointing performance after sales slowed.

Newcomers· Jan 7

The acquisition of Inari Medical ($NARI) by Stryker ($SYK) is a significant development, with Stryker agreeing to pay $80 per share in cash.
The M&A activity in the medical device sector is expected to be high, with cardio being a potential hotspot, according to Leerink.
The acquisition of Inari Medical at 8x EV/Sales multiple is being compared to another medical device company, $TMDX, which trades at 5.84x EV/Sales, implying potential upside for $TMDX.

Generated by AI

News

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investm...

2mo agomarkets.businessinsider.com

Argus raises Stryker stock price target on cyberattack recovery

2mo agoInvesting.com

Also Discussed

Investors talking about NARI also mention

#	Name	Attention
1	SWAV - ShockWave Medical, Inc.	——
2	PDS Biotechnology CorporationPDSB	0%-0.01
3	DAWN - Day One Biopharmaceuticals, Inc.	——
4	TransMedics Group, Inc.TMDX	0%-0.01
5	MYOV - Myovant Sciences Ltd.	——
6	BPMC - Blueprint Medicines Corporation	——
7	iRhythm Holdings, Inc.IRTC	0%0
8	SelectQuote Inc.SLQT	0%0
9	ADC Therapeutics S.A.ADCT	0%0
10	SWTX - SpringWorks Therapeutics, Inc.	——

Inari Medical, Inc.

Location

Social

What share of all stock conversation is about NARI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 17

The author believes $NARI has the potential to reach 137x+ and has been hitting new highs, with a recent 8K filing and significant increase in market capitalization.
The author has analyzed the top holders and team behind Inari Medical, Inc. and is confident in their price prediction, although a recent report suggests a high risk of rug pulls.
The author is optimistic about the future of $NARI, citing Elon Musk's involvement and the token's potential to become the next Grok Companion, with some analysts predicting a significant price increase.

Generated by AI

Sentiment

Of the messages about NARI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.17% +9.77
Bearish	—	—	—	1.83% -9.77

Bullish· Jan 8

The company's technology is considered good and has the backing of a respected top doctor in NYC.
The asset is undervalued and could be worth more than a billion dollars.
The stock could be an acquisition candidate for a larger company, similar to other medical tech companies that were previously out of favor.

Bearish· Nov 2

$NARI's price action is seen as irrational after upbeat guidance, with some investors adding positions around the 50 area.
The market is concerned about the company's acquisition, with some investors feeling that it will divert focus from the core business.
The stock's technical chart shows vulnerability, with a sell-off and significant volume, potentially indicating that a whale is betting against the stock.

Generated by AI

Topics

Of the messages about NARI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	43.57%
Announcements	—	—	—	12.35%
Controversies	—	—	—	0.23%
Earnings	—	—	—	0%
Macro	—	—	—	43.8%
Technical Analysis	—	—	—	0.06%

Earnings· Jan 9

NARI's preliminary Q4 revenue of $132.0M is up approximately 22% YoY, beating expectations.
Full-year 2023 revenue of $493.5M represents a 29% increase over 2022.
Inari Medical expects full-year 2024 revenue of $580M-$595M, reflecting continued growth.

Analysts· Mar 10

Morgan Stanley raised its price target for NARI to $126, maintaining an overweight rating.
BTIG Research raised its price target for NARI to $135, citing 65% year-over-year sales growth, and maintains a buy rating.
Canaccord Genuity raised its price target for NARI to $129, reiterating a buy rating.

Announcements· Jan 8

Stryker has agreed to acquire Inari Medical, Inc. (NARI) for $4.9 billion.
The deal involves Stryker purchasing Inari Medical, a medical device innovator, to expand its offerings in the field.
The acquisition is expected to enhance Stryker's capabilities in treating blood clots.

Generated by AI

Community

Of the messages about NARI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	83.33%	37.76%
Newcomers	100%	100%	16.67%	62.24%

Regulars· Jan 7

NARI was acquired by Stryker in an all-cash deal worth $4.9 billion, with a tender offer for $80 per share, a 60.74% premium.
Long-term investors are advised to "Buy low and Sell high" as NARI's stock has experienced dips below $40 in the past 12 months, and the buyout may be a good omen for the overall Biotech market.
NARI's acquisition by Stryker is reminiscent of the disappointing medtech acquisition of Volcano, with both experiencing multi-year drawdowns and disappointing performance after sales slowed.

Newcomers· Jan 7

The acquisition of Inari Medical ($NARI) by Stryker ($SYK) is a significant development, with Stryker agreeing to pay $80 per share in cash.
The M&A activity in the medical device sector is expected to be high, with cardio being a potential hotspot, according to Leerink.
The acquisition of Inari Medical at 8x EV/Sales multiple is being compared to another medical device company, $TMDX, which trades at 5.84x EV/Sales, implying potential upside for $TMDX.

Generated by AI

Inari Medical

Social

Jul 17

Bullish· Jan 8

Bearish· Nov 2

Earnings· Jan 9

Analysts· Mar 10

Announcements· Jan 8

Regulars· Jan 7

Newcomers· Jan 7

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Argus raises Stryker stock price target on cyberattack recovery

Also Discussed

Inari Medical, Inc.

Company Information

Location

Social

Jul 17

Bullish· Jan 8

Bearish· Nov 2

Earnings· Jan 9

Analysts· Mar 10

Announcements· Jan 8

Regulars· Jan 7

Newcomers· Jan 7

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Argus raises Stryker stock price target on cyberattack recovery

Also Discussed